PT2463283E - Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase - Google Patents
Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase Download PDFInfo
- Publication number
- PT2463283E PT2463283E PT121583181T PT12158318T PT2463283E PT 2463283 E PT2463283 E PT 2463283E PT 121583181 T PT121583181 T PT 121583181T PT 12158318 T PT12158318 T PT 12158318T PT 2463283 E PT2463283 E PT 2463283E
- Authority
- PT
- Portugal
- Prior art keywords
- glucokinase
- prevention
- treatment
- heterocyclic compounds
- mediated diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79370306P | 2006-04-20 | 2006-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2463283E true PT2463283E (pt) | 2014-08-27 |
Family
ID=38283722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT121583181T PT2463283E (pt) | 2006-04-20 | 2007-04-11 | Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP2463283B1 (pt) |
JP (1) | JP5190448B2 (pt) |
AR (1) | AR060533A1 (pt) |
CA (1) | CA2648852C (pt) |
CL (1) | CL2007001085A1 (pt) |
DK (1) | DK2463283T3 (pt) |
DO (1) | DOP2007000079A (pt) |
ES (1) | ES2487967T3 (pt) |
GT (1) | GT200700036A (pt) |
NL (1) | NL2000581C2 (pt) |
PE (1) | PE20080075A1 (pt) |
PL (1) | PL2463283T3 (pt) |
PT (1) | PT2463283E (pt) |
SI (1) | SI2463283T1 (pt) |
TW (1) | TW200808775A (pt) |
UY (1) | UY30296A1 (pt) |
WO (1) | WO2007122482A1 (pt) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2046755A2 (en) | 2006-07-24 | 2009-04-15 | F. Hoffmann-Roche AG | Pyrazoles as glucokinase activators |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CN101910131B (zh) | 2007-11-16 | 2014-04-23 | 里格尔药品股份有限公司 | 甲酰胺、磺酰胺和胺化合物及其使用方法 |
WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
EA018894B1 (ru) * | 2009-03-11 | 2013-11-29 | Пфайзер Инк. | N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция |
EP2406230A1 (en) * | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
AU2010317842A1 (en) | 2009-11-16 | 2012-07-12 | Mellitech | [1,5]-diazocin derivatives |
US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
SI2547679T1 (sl) | 2010-03-19 | 2015-12-31 | Pfizer Inc. | Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US20130197229A1 (en) | 2010-10-13 | 2013-08-01 | Christopher Matthews | Method of making azaindazole derivatives |
NZ609527A (en) | 2010-10-29 | 2014-03-28 | Pfizer | N1/n2-lactam acetyl-coa carboxylase inhibitors |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US9035067B2 (en) * | 2011-03-15 | 2015-05-19 | Bayer Intellectual Property Gmbh | N-(1,2,5-Oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides and their use as herbicides |
CN103492388A (zh) | 2011-04-22 | 2014-01-01 | 辉瑞大药厂 | 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物 |
WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
WO2013014569A1 (en) | 2011-07-22 | 2013-01-31 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA2853024C (en) | 2011-11-11 | 2017-08-22 | Pfizer Inc. | 2-thiopyrimidinones |
CA2869587A1 (en) | 2012-04-06 | 2013-10-10 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
MX360824B (es) | 2012-07-31 | 2018-11-15 | Univ Texas | Una combinación para inducir la formación de células beta de células de mamífero y uso de la misma. |
JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
EP2725030A1 (en) | 2012-10-29 | 2014-04-30 | Umicore AG & Co. KG | Ruthenium-based metathesis catalysts, precursors for their preparation and their use |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
EA032356B1 (ru) | 2014-03-17 | 2019-05-31 | Пфайзер Инк. | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств |
LT3536685T (lt) | 2014-04-04 | 2022-04-25 | Pfizer Inc. | Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių |
MD20160105A2 (ro) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |
CN104387348A (zh) * | 2014-10-27 | 2015-03-04 | 湖南华腾制药有限公司 | 一种苯并呋喃衍生物的制备方法 |
CN105669686B (zh) * | 2014-11-19 | 2018-08-03 | 上海合全药业股份有限公司 | 一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法 |
WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
EP3292109A1 (en) | 2015-05-05 | 2018-03-14 | Pfizer Inc | 2-thiopyrimidinones |
EP3303303A1 (en) | 2015-05-29 | 2018-04-11 | Pfizer Inc | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
CN107787322B (zh) | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
CA2995153A1 (en) | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
PT3341367T (pt) | 2015-08-27 | 2021-04-19 | Pfizer | Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4 |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド |
WO2017051276A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
WO2017151617A1 (en) | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
AU2017296338A1 (en) | 2016-07-14 | 2019-01-03 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
EA201991095A1 (ru) | 2016-11-03 | 2019-09-30 | Бристол-Маерс Сквибб Компани | Замещенные азотсодержащие соединения |
RU2644355C1 (ru) * | 2017-04-17 | 2018-02-09 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Соединения на основе пиридоксина, обладающие способностью активировать фермент глюкокиназу |
JP7305614B2 (ja) | 2017-07-19 | 2023-07-10 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
US11254660B2 (en) | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
US20210338776A1 (en) * | 2018-09-06 | 2021-11-04 | Yale University | Treatments against mosquito-borne viruses based on mosquito salivary gland proteins |
WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
EP3972596A1 (en) | 2019-05-20 | 2022-03-30 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
US20220363673A1 (en) | 2019-06-28 | 2022-11-17 | Pfizer Inc. | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
PE20231215A1 (es) | 2020-06-09 | 2023-08-17 | Pfizer | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos |
WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
TW202337429A (zh) | 2021-12-01 | 2023-10-01 | 美商輝瑞股份有限公司 | 支鏈酮酸脫氫酶激酶(bckdk)抑制劑及/或降解劑 |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4147694A (en) * | 1977-02-07 | 1979-04-03 | Riker Laboratories, Inc. | 8-(1H-Tetrazol-5-yl-carbamoyl)quinoline compounds |
US5707985A (en) * | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
US6387938B1 (en) | 1996-07-05 | 2002-05-14 | Mochida Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
JP5278983B2 (ja) * | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
US7148237B2 (en) * | 2001-03-01 | 2006-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
ATE404537T1 (de) * | 2002-08-13 | 2008-08-15 | Shionogi & Co | Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung |
GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
CN101142194B (zh) * | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | 吲哚衍生物,组合物及用作β-分泌酶抑制剂的方法 |
JP2009013065A (ja) * | 2005-10-14 | 2009-01-22 | Astellas Pharma Inc | 縮合へテロ環化合物 |
WO2007093507A1 (en) * | 2006-02-13 | 2007-08-23 | F. Hoffmann-La Roche Ag | Heterobicyclic sulfonamide derivatives for the treatment of diabetes |
-
2007
- 2007-04-11 ES ES12158318.1T patent/ES2487967T3/es active Active
- 2007-04-11 DK DK12158318.1T patent/DK2463283T3/da active
- 2007-04-11 EP EP12158318.1A patent/EP2463283B1/en active Active
- 2007-04-11 EP EP07734354A patent/EP2010520B1/en not_active Not-in-force
- 2007-04-11 WO PCT/IB2007/001035 patent/WO2007122482A1/en active Application Filing
- 2007-04-11 PL PL12158318T patent/PL2463283T3/pl unknown
- 2007-04-11 NL NL2000581A patent/NL2000581C2/nl not_active IP Right Cessation
- 2007-04-11 SI SI200731479T patent/SI2463283T1/sl unknown
- 2007-04-11 JP JP2009505990A patent/JP5190448B2/ja not_active Expired - Fee Related
- 2007-04-11 CA CA2648852A patent/CA2648852C/en not_active Expired - Fee Related
- 2007-04-11 PT PT121583181T patent/PT2463283E/pt unknown
- 2007-04-17 CL CL200701085A patent/CL2007001085A1/es unknown
- 2007-04-18 AR ARP070101665A patent/AR060533A1/es not_active Application Discontinuation
- 2007-04-19 TW TW096113772A patent/TW200808775A/zh unknown
- 2007-04-19 DO DO2007000079A patent/DOP2007000079A/es unknown
- 2007-04-19 GT GT200700036A patent/GT200700036A/es unknown
- 2007-04-19 PE PE2007000484A patent/PE20080075A1/es not_active Application Discontinuation
- 2007-04-19 UY UY30296A patent/UY30296A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NL2000581C2 (nl) | 2008-01-03 |
AR060533A1 (es) | 2008-06-25 |
EP2010520A1 (en) | 2009-01-07 |
ES2487967T3 (es) | 2014-08-25 |
CA2648852C (en) | 2012-12-11 |
CA2648852A1 (en) | 2007-11-01 |
JP5190448B2 (ja) | 2013-04-24 |
EP2010520B1 (en) | 2012-09-12 |
GT200700036A (es) | 2007-11-15 |
EP2463283A1 (en) | 2012-06-13 |
SI2463283T1 (sl) | 2014-09-30 |
PE20080075A1 (es) | 2008-02-07 |
JP2009534369A (ja) | 2009-09-24 |
DK2463283T3 (da) | 2014-08-18 |
PL2463283T3 (pl) | 2014-10-31 |
EP2463283B1 (en) | 2014-06-11 |
DOP2007000079A (es) | 2007-11-15 |
UY30296A1 (es) | 2007-11-30 |
CL2007001085A1 (es) | 2008-05-02 |
NL2000581A1 (nl) | 2007-10-23 |
TW200808775A (en) | 2008-02-16 |
WO2007122482A1 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2463283E (pt) | Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase | |
IL193473A0 (en) | Amide derivatives and their application for the treatment of g protein related diseases | |
HK1186125A1 (en) | Quinoline derivatives for the treatment of latent tuberculosis | |
ZA200707591B (en) | Dihyrothienopyrimidines for the treatment of inflammatory diseases | |
PL2001892T3 (pl) | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych | |
GB0605469D0 (en) | Multimers of heterocyclic compounds and their use | |
EP2018863A4 (en) | FUSED HETEROCYCLIC COMPOUND AND USE | |
IL178860A (en) | Certain chemical entities, preparations and processes | |
EP2118074A4 (en) | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIAC DISEASES | |
IL179210A0 (en) | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | |
ZA200708033B (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
EP2007790A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | |
HU0500145D0 (en) | Composition for the treatment of oral diseases | |
IL188894A0 (en) | Compounds for treatment of lipase-mediated diseases | |
ZA200705160B (en) | Quinoline derivatives for the treatment of latent tuberculosis | |
HK1185345A1 (zh) | 用於預防和治療心血管疾病的化合物 | |
GB0428218D0 (en) | Medicament for Treatment of Inflammatory Diseases | |
ZA200606780B (en) | Compounds for the treatment of diseases | |
GB0425073D0 (en) | Compounds for the treatment of diseases | |
GB0420867D0 (en) | Compounds for the treatment of diseases | |
IL177531A0 (en) | Compounds for the treatment of diseases | |
AP2006003743A0 (en) | Compounds useful for the treatment of diseases | |
GB0425064D0 (en) | Compounds useful for the treatment of diseases | |
IL202502A0 (en) | Agents for the treatment of inflammatory diseases and methods of using same |